AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 APR 3 - (NewsRx.com & NewsRx.net) -- Thymidylate synthase and thymidine are valid markers for selecting breast cancer therapy.
According to a study from Japan, "thymidine phosphorylase (dThdPase) is identical to platelet-derived endothelial cell growth factor, and has an angiogenic activity in experimental models and human solid tumors."
"A critical step in the de novo pathway of DNA synthesis is the production of the pyrimidine nucleotide dTMP from dump and this reaction is catalyzed by thymidylate synthase (TS). Both dThdPase and TS levels seemed to be related to response to 5-fluorouracil (5-FU) therapy in different types of human solid tumors," stated O. Ogura and coauthors, Tohoku University, Institute of Development, Aging, and Cancer.
"The present study evaluated dThdPase and TS expression levels by immunohistochemistry and reverse transcriptase-polymerase chain reaction (RT-PCR), using a same set of 39 breast carcinoma tissues for both methods. An inverted-relationship in the expression levels of TS and dThdPase was observed," said investigators.
"Further, immunohistochemical analysis may be a better tool than analysis by RT-PCR in detection of dThdPase and ...
Source: HighBeam Research, Thymidylate synthase and thymidine are valid markers for selecting...